Dr. Andrei Yudin

Professor Andrei K. Yudin is the Canada Research Chair in Medicine by Design at the Department of Chemistry, University of Toronto. Yudin received his undergraduate degree at the Moscow State University in 1992. He subsequently worked in the laboratories of G. K. S. Prakash and George A. Olah at USC, where he received his PhD in 1996. Following postdoctoral training in the laboratory of K. Barry Sharpless at the Scripps Research Institute, Professor Yudin started his independent career at the University of Toronto in 1998. He became an Associate Professor in 2002, which was followed by promotion to the rank of a Full Professor in 2007. Between January 2015 and 2018, Professor Yudin has served as the Chair of the Board for Organic and Biomolecular Chemistry. Yudin is currently an Associate Editor for Chemical Science. He is a Fellow of the Royal Society of Chemistry (UK), a Fellow of the Royal Society of Canada and the winner of the 2019 Lemieux Award for his work on boron chemistry. He also received 2019 Killam Fellowship that recognized his fundamental contributions to reaction design, 2017 Alfred Bader Award for his work on peptide macrocycles, 2015 Bernard Belleau Award for his work in the area of drug discovery, and 2010 Royal Society of Canada Rutherford Memorial Medal for his work on amphoteric structures. Yudin has been active in translating fundamental discoveries into medicines. Encycle Therapeutics (acquired by Zealand Pharma in 2019), has developed therapeutic agents using peptide macrocyclization.